Innovative solutions revolutionize global expression profiling of limited and degraded samples.
Using our proprietary technologies as the foundation of products, NuGEN develops and commercializes solutions for high-sensitivity nucleic acid amplification and target preparation. With these solutions, life scientists can generate more meaningful answers, increase productivity, and achieve more significant discoveries in their quest to understand the molecular basis of disease, to discover novel biomarkers, and to identify and validate new drug targets.
NuGEN uniquely enables researchers to perform robust, high-fidelity expression analysis from limited and highly compromised clinical specimens. These solutions help researchers unlock discoveries in previously inaccessible samples such as formalin-fixed paraffin-embedded (FFPE), laser-captured, micro-dissected tissue (LCM), and others.
Founded in 2000, NuGEN Technologies, Inc. is privately held and headquartered in San Carlos, California near the heart of Silicon Valley. The company has commercialized numerous proprietary RNA amplification and labeling technologies and products for discovery and clinical research applications.